Literature DB >> 15168368

Advances in the treatment of Crohn's disease.

Laurence J Egan1, William J Sandborn.   

Abstract

The medical therapy of Crohn's disease has improved considerably in recent years. In large part, this is due to the introduction of new efficacious agents, both "biologics" and traditional small molecules. Further study of older drugs has also advanced our ability to devise the optimum approach to individual Crohn's disease patients by better clarifying the benefits, adverse effects, and means to optimize doses of established medications. In this review, we present an evidence-based approach to the medical management of active Crohn's disease, Crohn's disease in remission, and perianal Crohn's disease that emphasizes recent advances that have come from the results of randomized controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168368     DOI: 10.1053/j.gastro.2004.01.062

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 2.  Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

Authors:  Chandrashekhar Thukral; Adam Cheifetz; Mark A Peppercorn
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Surgical predictors of recurrence of Crohn's disease after ileocolonic resection.

Authors:  Marco Scarpa; Cesare Ruffolo; Eugenia Bertin; Lino Polese; Teresa Filosa; Daniela Prando; Duilio Pagano; Lorenzo Norberto; Mauro Frego; Davide F D'Amico; Imerio Angriman
Journal:  Int J Colorectal Dis       Date:  2007-05-30       Impact factor: 2.571

4.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

5.  Frequency and risk factors of postoperative recurrence of Crohn's disease after intestinal resection in the Chinese population.

Authors:  Yi Li; Weiming Zhu; Lugen Zuo; Wei Zhang; Jianfeng Gong; Lili Gu; Lei Cao; Ning Li; Jieshou Li
Journal:  J Gastrointest Surg       Date:  2012-05-04       Impact factor: 3.452

6.  Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.

Authors:  L Biancone; A Orlando; A Kohn; E Colombo; R Sostegni; E Angelucci; F Rizzello; F Castiglione; L Benazzato; C Papi; G Meucci; G Riegler; C Petruzziello; F Mocciaro; A Geremia; E Calabrese; M Cottone; F Pallone
Journal:  Gut       Date:  2005-08-24       Impact factor: 23.059

7.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Authors:  Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

8.  Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice.

Authors:  Tara A Willson; Ingrid Jurickova; Margaret Collins; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

9.  Lipid and phospholipid profile after bowel resection for Crohn's disease.

Authors:  Giovanna Romanato; Marco Scarpa; Cesare Ruffolo; Raffaella Marin; Sabina Zambon; Silvia Zanoni; Silvia Basato; Teresa Filosa; Fabio Pilon; Imerio Angriman; Enzo Manzato
Journal:  Int J Colorectal Dis       Date:  2008-07-03       Impact factor: 2.571

Review 10.  Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.

Authors:  Giovanni-C Actis; Rinaldo Pellicano; Mario Rizzetto; Muhammad Ayoubi; Nicola Leone; Gianfranco Tappero; Paola Pazienza; Floriano Rosina
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.